這項隨機臨床試驗將評估在根治性化放療基礎上加入空間分次放射治療（SFRT）能否改善局部晚期子宮頸癌患者的結局。計劃接受根治性化放療的FIGO 2018分期IIB至IVA期成年子宮頸癌患者，將按1:1比例隨機分配至SFRT組或對照組。 兩組均將接受體外放射治療
適應症：Cervical Cancer
收案條件
納入條件
- Age ≥18 years.
- Histologically confirmed cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
- FIGO 2018 stage IIB to IVA disease with primary tumor ≥4cm
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Planned to receive definitive chemoradiotherapy.
- Able and willing to provide written informed consent.
排除條件
- Severe medical comorbidities that preclude the safe administration of radiotherapy.
- Pregnancy or, for women of childbearing potential, inability to use effective contraception.
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。